Iberdrola International BV (TG:IRBH)
Historical Stock Chart
From Jul 2019 to Jul 2024
ImmuneRegen BioSciences' Homspera(TM) Deemed Dermally Non-Toxic
Pre-Clinical Studies Bode Well for Future Hair Loss Applications
SCOTTSDALE, Ariz., March 3 /PRNewswire-FirstCall/ -- ImmuneRegen BioSciences, a
wholly owned subsidiary of IR BioSciences Holdings, Inc. (BULLETIN BOARD: IRBH)
, today announced their toxicity study for their proprietary compound Homspera
showed no levels of toxicity, such as skin irritation, in tested animals. With
these results, the company is moving forward in targeting male pattern baldness
as a potential application for Homspera.
The study was performed by AppTec Laboratory Services of St. Paul, MN and was
designed to evaluate the allergenic potential or sensitizing capacity for the
company's substance P compound. According to the AppTec results report,
"ImmuneRegen BioSciences, Inc., Homspera [Sar9, met (O2)11] -- Substance P ...
was classified as acceptable in regard to dermal sensitization."
"Obviously we're thrilled with these test results," states Michael K. Wilhelm,
president of IR BioSciences Holdings, Inc. "We're currently researching the
effectiveness of Homspera in topical applications for conditions such as male
pattern baldness and loss of hair from chemotherapy. These results put us one
stepcloser to making these applications a reality."
About the study
The study utilized fifteen guinea pigs, ten experimental and five controls.
Patches with topical doses of Homspera [Sar9, met (O2)11] -- Substance P were
applied to the shaved left flanks of the ten experimental guinea pigs, which
were then bandaged to secure the patches. The bandaging and patches were
removed after six to eight hours of exposure and each guinea pig was checked
after roughly 24 hours for signs of erythema and edema. The procedure was
repeated once a week for three weeks for a total of three inductions. The
tested guinea pigs showed no signs of erythema or edema.
Fourteen days after completing the topical induction process, patches with
topical doses were appliedto the shaved right flanks of the ten experimental
guinea pigs, which were then bandaged to secure the patches. Again, the
bandaging and patches were removed after six to eight hours of exposure. At the
24, 48 and 72-hour marks, each testing area waswiped gently with a 70% isporpyl
alcohol-soaked gauze sponge and was observed for irritation and sensitization
reactions. Again, the tested guinea pigs showed no signs of erythema or edema.
About AppTec
AppTec Laboratory Services is a unique single source for the
biopharmaceutical/biotechnology and medical device/medical product industries --
offering testing, contract research and development, and specialized cGMP
manufacturing services.
About IR BioSciences Holdings, Inc.
IR BioSciences Holdings, Inc. (OTC:IRBH) (BULLETIN BOARD: IRBH) , formed in
2003, is the sole owner of ImmuneRegen BioSciences, Inc., a biotechnology
company engaged in the research and development of applications utilizing
modified Substance P, a naturally occurring immunomodulator. Derived from
homeostatic substance P, ImmuneRegen has named their proprietary compound
"Homspera." The Company's initial focus is on the continuing development of
Homspera for various applications for use in improving pulmonary function and
stimulating the human immune system. For more information, please visit the
company's website at http://www.immuneregen.com/ .
About Homspera
ImmuneRegen's patents and continued substance P research are derived from
discoveries made during research funded by the Air Force Office of Scientific
Research in the early 1990s. During this research, Dr. Mark Witten and his
associates observed that the exposure of animals to jet fuels resulted in
pathological changes in the lung and immune systems of those exposed. It was
also observed that such exposure resulted in depletion of substance P from the
lungs of the animals. These studies further showed that the administration of
substance P may help prevent and reverse the effects of jet fuel exposure in the
lungs, as well as protect and regenerate the immune system. The immune findings
led to early research on the treatment of exposure to acute radiation and on the
possible reversal of lung damage caused by ARDS and cigarette smoke.
Statements about the Company's future expectations, including future revenues
and earnings, and all other statements in this press release other than
historical facts, are "forward-looking statements" within the meaning of Section
27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of
1934, and as that term is defined in the Private Securities Litigation Reform
Act of 1995. The Company intends that such forward-looking statements be
subject to the safe harbors created thereby. The Company's actual results could
differ materially from expected results as a result of a number of factors,
including the uncertainties inherent in research collaborations, clinical trials
and product development programs, the evaluation of potential opportunities, the
level of corporate expenditures, capital market conditions, and others set forth
in the Company's periodic report on Form 8-K as filed with the Securities and
Exchange Commission on July 7, 2003.
DATASOURCE: ImmuneRegen BioSciences, Inc.
CONTACT: Media, Michelle Derden of Spelling Communications,
+1-310-477-9500, ; or Investors, Tony Schor of
InvestorAwareness, +1-847-945-2222, , both for ImmuneRegen
BioSciences, Inc.
Web site: http://www.immuneregen.com/